Charles Schwab Investment Management Inc. Purchases 40,968 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Charles Schwab Investment Management Inc. raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 753,363 shares of the specialty pharmaceutical company's stock after purchasing an additional 40,968 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.36% of Supernus Pharmaceuticals worth $27,242,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Smartleaf Asset Management LLC raised its stake in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 870 shares during the period. Newbridge Financial Services Group Inc. bought a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $72,000. Venturi Wealth Management LLC acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth approximately $92,000. KBC Group NV boosted its stake in Supernus Pharmaceuticals by 53.1% in the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock valued at $97,000 after purchasing an additional 929 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new position in Supernus Pharmaceuticals in the 4th quarter valued at $211,000.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, March 16th. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Remove Ads

Supernus Pharmaceuticals Price Performance

SUPN traded down $0.20 on Friday, hitting $32.13. 856,005 shares of the stock were exchanged, compared to its average volume of 467,890. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of 30.02 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The business has a 50-day moving average of $35.79 and a two-hundred day moving average of $35.09.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the company's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This represents a 48.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,104 shares of company stock valued at $440,263. Company insiders own 9.30% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.